Krka d. d - Asset Resilience Ratio
Krka d. d (KRK) has an Asset Resilience Ratio of 11.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Krka d. d's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Krka d. d's Asset Resilience Ratio has changed over time. See KRK equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Krka d. d's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KRK market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł340.29 Million | 11.18% |
| Total Liquid Assets | zł340.29 Million | 11.18% |
Asset Resilience Insights
- Moderate Liquidity: Krka d. d has 11.18% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Krka d. d Industry Peers by Asset Resilience Ratio
Compare Krka d. d's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
Annual Asset Resilience Ratio for Krka d. d (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Krka d. d.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.46% | zł257.29 Million ≈ $70.81 Million |
zł3.04 Billion ≈ $837.38 Million |
-0.12pp |
| 2024-12-31 | 8.58% | zł244.34 Million ≈ $67.25 Million |
zł2.85 Billion ≈ $784.09 Million |
+6.04pp |
| 2023-12-31 | 2.53% | zł70.02 Million ≈ $19.27 Million |
zł2.76 Billion ≈ $760.77 Million |
+0.65pp |
| 2022-12-31 | 1.89% | zł50.70 Million ≈ $13.95 Million |
zł2.69 Billion ≈ $739.64 Million |
-4.18pp |
| 2021-12-31 | 6.07% | zł153.96 Million ≈ $42.37 Million |
zł2.54 Billion ≈ $698.41 Million |
+5.67pp |
| 2020-12-31 | 0.40% | zł8.97 Million ≈ $2.47 Million |
zł2.24 Billion ≈ $615.25 Million |
+0.30pp |
| 2019-12-31 | 0.10% | zł2.17 Million ≈ $598.32K |
zł2.18 Billion ≈ $601.24 Million |
-0.05pp |
| 2018-12-31 | 0.15% | zł2.92 Million ≈ $803.63K |
zł1.99 Billion ≈ $546.32 Million |
+0.64pp |
| 2017-12-31 | -0.50% | zł-9.54 Million ≈ $-2.63 Million |
zł1.92 Billion ≈ $528.17 Million |
-0.50pp |
| 2016-12-31 | 0.00% | zł77.00K ≈ $21.19K |
zł1.91 Billion ≈ $526.08 Million |
0.00pp |
| 2015-12-31 | 0.00% | zł79.00K ≈ $21.74K |
zł1.81 Billion ≈ $497.92 Million |
-0.03pp |
| 2014-12-31 | 0.03% | zł575.00K ≈ $158.25K |
zł1.80 Billion ≈ $494.21 Million |
-0.01pp |
| 2013-12-31 | 0.05% | zł792.00K ≈ $217.97K |
zł1.76 Billion ≈ $484.35 Million |
+0.00pp |
| 2012-12-31 | 0.04% | zł679.00K ≈ $186.87K |
zł1.63 Billion ≈ $447.70 Million |
+0.00pp |
| 2011-12-31 | 0.04% | zł602.00K ≈ $165.68K |
zł1.53 Billion ≈ $422.19 Million |
0.00pp |
| 2010-12-31 | 0.04% | zł653.00K ≈ $179.72K |
zł1.49 Billion ≈ $409.58 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more